Vivani Medical SEC Filings

Vivani Medical entered a Share Purchase Agreement effective August 11, 2025 to sell 7,936,507 shares of common stock at $1.26 per share, the last reported sale price on that date. The placement is expected to generate approximately $10.0 million in gross proceeds to the Company, with issuances occurring over multiple closings through July 15, 2026, each subject to closing conditions.

The Company stated that no warrants or discounts were provided and that no placement agent or investment banking fees were incurred. The Shares will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506 of Regulation D and have not been registered for resale. The filing attaches a Share Purchase Agreement and a press release and corporate slide presentation as exhibits.

Form 4 Filing Details: Aaron Mendelsohn, Director of Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy.

Key Transaction Details:

• Granted 35,135 stock options to purchase common stock
• Exercise price set at $1.27 per share
• Options expire on June 23, 2035
• Vesting occurs on earlier of: first grant anniversary or next annual stockholder meeting

The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025. This transaction represents standard annual director compensation and indicates continued board engagement. The vesting structure aligns with typical corporate governance practices for director equity compensation.

Vivani Medical (VANI) reported insider trading activity through a Form 4 filing for Director and 10% Owner Gregg Williams. The filing details two significant option-related transactions:

• On June 24, 2025, Williams was granted 35,135 non-qualified stock options with an exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first.
• A correction was made to a previous January 1, 2025 option grant, adjusting the total beneficial ownership from 76,757 to 76,393 options (exercise price $1.16) due to a clerical error. These options vest quarterly.

The transactions reflect standard director compensation practices and demonstrate continued insider equity participation in the company. The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025.

Vivani Medical Director Wilford Dean Baker received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy. The grant details include:

• 35,135 options to purchase common stock
• Exercise price of $1.27 per share
• Expiration date of June 23, 2035
• Vesting occurs in full on either the first grant anniversary or next annual stockholder meeting, whichever comes first

The Form 4 filing, signed by Attorney-in-fact Adam Mendelsohn on June 26, 2025, represents a standard annual director compensation grant. The vesting is contingent on Baker's continued service through the vesting date. This equity compensation aligns the director's interests with those of shareholders through long-term stock ownership potential.

Director Daniel Bradbury reported two key transactions in Vivani Medical (VANI) stock options:

• Acquired 35,135 non-qualified stock options on June 24, 2025, with exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first. This was part of the annual director compensation policy.
• Correction to previous grant from January 1, 2025: Total options adjusted down from 50,059 to 49,822 (reduction of 237) due to clerical error. These options have a $1.16 exercise price and vest quarterly.

The transactions reflect standard board compensation practices and administrative corrections rather than open market trading activity. All holdings are directly owned, with no indirect beneficial ownership reported.

Form 4 filing reveals that Alexandra L. Popoff, Director at Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025. Key details of the transaction:

• Granted 35,135 stock options to purchase common stock
• Exercise price set at $1.27 per share
• Options expire on June 23, 2035
• Vesting occurs on earlier of: - First anniversary of grant date - Next annual stockholder meeting

This grant was made as part of the company's Non-Employee Director Compensation Policy. The vesting is subject to continued service through the vesting date. The filing was submitted through an attorney-in-fact on June 26, 2025.

Vivani Medical, Inc. (Nasdaq: VANI) filed a Form 8-K to disclose the voting results of its 24 June 2025 Annual Meeting of Stockholders. A quorum was achieved with 37.1 million of 59.2 million outstanding shares represented. All six director nominees—Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn and Daniel Bradbury—were elected, each receiving roughly 25 million votes in favor versus approximately 0.4-0.6 million withheld, and 11.8 million broker non-votes. Stockholders also (1) ratified BPM LLP as independent auditor for fiscal 2025 with 36.5 million votes in favor and minimal opposition, and (2) approved, on a non-binding basis, executive compensation with 23.1 million votes for, 0.6 million against, 1.7 million abstentions and 11.8 million broker non-votes. No other matters were presented.